The Role of Inflammatory Pathway Genetic Variation on Maternal Metabolic Phenotypes during Pregnancy

Margrit Urbanek¹*, M. Geoffrey Hayes¹, Hoon Lee¹, Rachel M. Freathy², Lynn P. Lowe³,⁷, Christine Ackerman¹, Nadereh Jafari⁴, Alan R. Dyer³,⁷, Nancy J. Cox⁵, David B. Dunger⁶, Andrew T. Hattersley², Boyd E. Metzger¹,², William L. Lowe Jr¹

¹Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, ²Genetics of Complex Traits, Peninsula College of Medicine and Dentalistry, University of Exeter, Exeter, United Kingdom, ³Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, ⁴Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom, ⁵Genomics Core, Center for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America, ⁶Department of Human Genetics, University of Chicago, Chicago, Illinois, United States of America, ⁷Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom, ⁸HAPO Study Cooperative Research Group, Chicago, Illinois, United States of America

Abstract

**Background:** Since mediators of inflammation are associated with insulin resistance, and the risk of developing diabetes mellitus and gestational diabetes, we hypothesized that genetic variation in members of the inflammatory gene pathway impact glucose levels and related phenotypes in pregnancy. We evaluated this hypothesis by testing for association between genetic variants in 31 inflammatory pathway genes in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) cohort, a large multiethnic multicenter study designed to address the impact of glycemia less than overt diabetes on pregnancy outcome.

**Results:** Fasting, 1-hour, and 2-hour glucose, fasting and 1-hour C-peptide, and HbA1c levels were measured in blood samples obtained from HAPO participants during an oral glucose tolerance test at 24-32 weeks gestation. We tested for association between 458 SNPs mapping to 31 genes in the inflammatory pathway and metabolic phenotypes in 3836 European ancestry and 1713 Thai pregnant women. The strongest evidence for association was observed with TNF alpha and HbA1c (rs1052248; 0.04% increase per allele C; p-value = 4.4x10⁻⁵), RETN and fasting plasma glucose (rs1423096; 0.7 mg/dl decrease per allele A; p-value = 1.3x10⁻⁴), IL8 and 1 hr plasma glucose (rs2886920; 2.6 mg/dl decrease per allele T; p-value = 1.3x10⁻⁴), ADIPOR2 and fasting C-peptide (rs2041139; 0.55 ug/L decrease per allele A; p-value = 1.4x10⁻⁴), LEPR and 1 hour C-peptide (rs1171278; 0.62 ug/L decrease per allele T; p-value = 2.4x10⁻⁴), and IL6 and 1-hour plasma glucose (rs6954897; –2.29 mg/dl decrease per allele G; p-value = 4.3x10⁻⁴).

**Conclusions:** Based on the genes studied in this survey the inflammatory pathway is unlikely to have a strong impact on maternal metabolic phenotypes in pregnancy although variation in individual members of the pathway (e.g. RETN, IL8, ADIPOR2, LEPR, IL6, and TNF alpha) may contribute to metabolic phenotypes in pregnant women.

Citation: Urbanek M, Hayes MG, Lee H, Freathy RM, Lowe LP, et al. (2012) The Role of Inflammatory Pathway Genetic Variation on Maternal Metabolic Phenotypes during Pregnancy. PLoS ONE 7(3): e32958. doi:10.1371/journal.pone.0032958

Editor: Sunil K. Ahuja, South Texas Veterans Health Care System and University Health Science Center San Antonio, United States of America

Received May 20, 2011; Accepted February 8, 2012; Published March 30, 2012

Copyright: © 2012 Urbanek et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study is funded by grants R01 DK067459, R01-HD34242 and R01-HD34243 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Diabetes, Digestive, and Kidney Diseases, by the National Center for Research Resources (M01-RR00408, M01-RR00080), and by the American Diabetes Association. RMF is funded by a Sir Henry Wellcome Postdoctoral Fellowship (Wellcome Trust grant: 085541/Z/08/Z). ATH is employed as a core member of the Peninsula NIHR Clinical Research Facility. Support has also been provided to local field centers by Diabetes UK (RD04/ 0002756), Kaiser Permanente Medical Center, KK Women’s and Children’s Hospital, Mater Mother’s Hospital, Nova Nordisk, the Myre Sim Fund of the Royal College of Physicians of Edinburgh, and the Howard and Carol Bernick Family Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Support has also been provided to local field centers by Kaiser Permanente Medical Center, KK Women’s and Children’s Hospital, Mater Mother’s Hospital, Nova Nordisk. These funds were used in the recruitment and phenotyping of the HAPO subjects and do not directly impact the research described in this study. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: m-urbanek@northwestern.edu

Introduction

There is a well-established link between obesity, diabetes, and insulin resistance and chronic low levels of inflammation (reviewed in [1]). This link is based on multiple lines of evidence. First, markers of the inflammatory response such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1β (IL-1β), interleukin 6 (IL-6), plasminogen activator inhibitor 1 (PAI1), and C-reactive protein (CRP) are strongly associated with features of the metabolic syndrome in humans [2,3,4,5,6,7,8,9,10,11,12,13, 14,15,16,17]. Second, mouse knockout strains of IL-6 [18], TNF-alpha [19], PAI-1 [20], IL-1β [21], IL-1α [22], resistin [23], monocytectoid protein-1 (MCP-1) [24,25], intracellular adhesion molecule 1 (ICAM-1) [26], nitric oxide synthase (iNOS) [27], inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-β) [28,29], jun N-terminal kinase 1 (JNK1) [30], and
suppressor of cytokine signaling 1 (SOCS1) [31] have perturbations in measures of insulin resistance or blood glucose levels. Third, patients with chronic inflammatory conditions such as chronic hepatitis C, rheumatoid arthritis, and inflammatory lung disease are at increased risk for developing diabetes (reviewed in [32,33]). Lastly, genetic or pharmacological removal or reduction of inflammatory factors can protect humans and high-risk rodent models against insulin resistance independent of obesity, indicating that the inflammatory response plays a primary role in the etiology of insulin resistance and diabetes rather than an effect secondary to obesity.

Many of the effects of the inflammatory response on insulin resistance are mediated via the nuclear factor kappa B (NF-kB) signalling pathway [29,34,35,36]. NF-kB is a transcription factor that regulates multiple cellular processes including cell growth, survival and division, apoptosis, stress, hypoxia, and immune function. Upon stimulation by cytokines, NF-kB is activated by IKK-β and translocated into the nucleus where it regulates transcription of a broad range of genes including the pro-inflammatory cytokines, IL-1, IL-6 and TNF-alpha. Ablation of IKK-β in the liver of mice reduces the induction of IL-1β, IL-1β, IL-6, and RANTES cytokine mRNA in liver by high fat diet [37]. Several studies have demonstrated the effects of disruption of the NF-kB pathway on insulin sensitivity. For example elevated levels of TNF-alpha result in insulin resistance [36,39,39,40,41]. In hepatocytes, over-expression of a specific inhibitor of NF-kB activation, IkB, prevents an IL-1β-induced decrease in insulin sensitivity [37]. Furthermore, nonsteroid anti-inflammatory drugs, including aspirin and sodium salicylate which suppress IkB proteolysis by inhibiting IKK-β [42], improve insulin resistance and glycemia [43,44].

During pregnancy the levels of the pro-inflammatory cytokines CRP and TNF-alpha are positively associated with fasting insulin and body mass index (BMI), respectively [45]. In women with gestational diabetes, levels of the anti-inflammatory cytokine, adiponectin, are negatively associated with gestational diabetes while TNF-alpha and its soluble receptors sTNFR-1 and sTNFR-2 are positively associated [46,47]. Furthermore, Lowe et al have shown that non diabetic pregnant women levels of the pro-inflammatory cytokines PAI-1 and CRP are positively associated with maternal glucose, BMI and C-peptide levels while the levels of the anti-inflammatory cytokine, adiponectin, are negatively correlated with the same phenotypes [49].

To date inflammatory pathway genes have not been shown to play a major role in type 2 diabetes or glucose tolerance. However, most of these results are based on genome wide association studies (GWAS) which do not always provide sufficient genetic coverage of any given gene region. The more exhaustive tagging approach possible in a candidate gene screen may, therefore, detect genetic loci not identified by GWAS.

Since pregnancy is an insulin resistant state, the inflammatory pathway may also be important in glucose regulation during pregnancy and the development of gestational diabetes. To determine whether variation within inflammatory pathway genes impacts glucose regulation during pregnancy and the development of gestational diabetes we tested for association between 31 genes (Table 1) within the inflammatory gene pathway densely tagged with 450 genetic single nucleotide polymorphisms (SNPs, Tables 2 and 3) and measures of maternal metabolism in 5549 mothers of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) cohort, a large multiethnic, multicenter study designed to address the impact of glycemia less than overt diabetes on pregnancy outcome [49].

**Results**

To evaluate the impact of the inflammatory gene pathway on glycemia during pregnancy we carried out an association study. We genotyped 508 SNPs mapping to 31 inflammatory genes (Tables 1, 2, 3) in 6218 pregnant women of the HAPO cohort. We tested for association between these genetic markers and six maternal metabolic phenotypes (fasting, 1-hour and 2-hour glucose levels from the OGTT, fasting and 1-hour C-peptide levels from the OGTT, and HbA1C). Each phenotype was tested under a minimally adjusted statistical model and a fully adjusted model.

**Association Testing**

The most statistically significant results of the association analyses are shown in Table 4. Two models were analyzed for each outcome. Model I was a minimally adjusted model that included adjustment for field center, ethnicity using the first two principal components, maternal age, parity, gestational age at OGTT, and neonatal gender. Model II was the fully adjusted model, adjusting for all covariates included in model I as well as mean arterial pressure at OGTT, maternal BMI at OGTT, and maternal height at OGTT. While none of our findings reach formal genome wide statistical significance (p-value<1×10^-8 [50]), several SNPs do show evidence for association (defined as p<5×10^-4) with maternal phenotypes during pregnancy. We arbitrarily selected p<5×10^-4 as nominally significant since it corresponds to a corrected p-value of 0.05 after correction for 100 independent gene regions and the 508 SNPs analyzed in the study fell into ~100 independent linkage disequilibrium blocks.

**Association with glucose levels**

Multiple genes showed evidence for association with glucose levels. The strongest evidence for association with glucose levels was with variants in the genomic region for resistin (RETN). There was evidence for association with the SNP rs1423096, which maps 5 kb 5’ to RETN and fasting plasma glucose (FPG) levels (p-value 1.1×10^-4 with Model 1) in the complete cohort (Table 4; Figure 1A). Although each cohort by itself demonstrated only moderate evidence for association, the effect size of rs1423096 was very similar in the European ancestry (β = -0.74 to -0.84 mg/dl, Thai (β = -0.47 to -0.55 mg/dl), and combined cohorts (β = -0.62 to -0.72 mg/dl) under each model tested. Thus, these data support a role for rs1423096 on FPG levels in both cohorts and demonstrate that this effect is not sensitive to potential confounding factors.

Two variants (rs2227306, and rs2886920) in the gene encoding interleukin 6 (IL6) were associated with 1-hour plasma glucose levels (1-hour PG) at p<5×10^-4 with essentially the same effect size for each SNP (Table 4; Figure 1B). Although the evidence for association is substantially stronger in the European ancestry cohort, the effect, while not statistically significant, is in the same direction in the Thai cohort. These two SNPs are in linkage disequilibrium and, therefore, are likely detecting the same genetic signal.

A SNP mapping 17 kb upstream of interleukin 6, IL6 (rs6954897) is negatively associated with 1-hour plasma glucose levels with Model 1 in the European ancestry cohort (β = -2.245, p-value = 9.3×10^-3; Table 4, Figure 1C). Although the effect size was very similar in the Thai population (β = -3.044) the findings did not reach statistical significance due to the reduced MAF (0.056 vs. 0.428 in the European ancestry cohort) of rs6954897 and smaller sample size in the Thai population. However, in the analysis of all samples in model 1, this SNP demonstrated...
Association with 1-hour plasma glucose \((\beta = -2.291, \text{p-value} = 4.3 \times 10^{-4}; \text{Table 4, Fig. 1C})\).

### Association with C-peptide levels

The adiponectin receptor 2 (ADIPOR2) SNP, rs2041139, was associated with fasting C-peptide levels in the European ancestry cohort \((\beta = 0.548, \text{p-value} = 1.4 \times 10^{-4} \text{ in Model 1; Table 4, Figure 1D})\) but only to a much lesser degree in the Thai cohort \((\beta = 0.031, \text{p-value} = \text{not significant})\). It should be noted that the minor allele frequency (MAF) for rs2041139 is very low in the Thai population (MAF = 0.005); therefore the findings at this locus may not be very robust and need to be interpreted with caution.

Two SNPs within the leptin receptor, LEPR (rs1627238 and rs1171278) were associated with 1-hour C-peptide levels in the Thai cohort (Table 4 and Figure 1E; \(\beta = 0.61-0.62, \text{p-value} = 2.9 \times 10^{-4}\) and \(\text{p-value} = 2.4 \times 10^{-4}\) respectively). Neither marker showed significant evidence for association in the European ancestry cohort. Both markers map within a two kb fragment of intron 2 of LEPR and are in strong LD with each other (Figure 1E).

### Association with HbA1C levels

The strongest evidence for association with HbA1C and in the overall study \((\text{p-value} = 4.42 \times 10^{-5})\) was observed with rs1052248 in the tumor necrosis factor alpha gene, TNF, under the fully adjusted model in the complete cohort (Table 4; Figure 1G). rs1052248 was associated with HbA1c with somewhat stronger effect size in the Thai cohort than the European derived cohort \((\beta = 0.057 \text{ vs. } 0.029 \text{ in Model 2})\). One other SNP in TNF (rs11575839) also have evidence of association \((\text{p-value} = 5.0 \times 10^{-4})\) with HbA1c. In each case the strongest evidence was in the combined cohort with some evidence for association in both populations.

SNPs in several genes showed evidence for association in only one cohort or the effect was in the opposite direction in the Thai and European ancestry cohorts (Table 4). These include rs7554506 in adiponectin receptor 1, ADIPOR1, with 1-hour C-peptide levels under the fully adjusted model (Model 2). This association was only observed in the Thai cohort.

---

**Table 1. List of genes.**

| Gene ID | Chr. Location | Gene name |
|---------|---------------|-----------|
| ADIPOQ  | 3q27.3        | adiponectin precursor |
| ADIPOR1 | 1q23.1        | adiponectin receptor 1 |
| ADIPOR2 | 12p13.33      | adiponectin receptor 2 |
| CCL2    | 17q12         | small inducible cytokine A2 precursor |
| CRP     | 1q32.2        | C-reactive protein precursor |
| CTLA4   | 2q33.2        | cytotoxic T-lymphocyte-associated protein 4 |
| IFIH1   | 2q24.2        | Interferon-induced helicase C domain-containing protein 1 |
| IL10    | 1q32.1        | interleukin 10 precursor |
| IL18    | 11q23.1       | interleukin 18 proprotein |
| IL18R1  | 2q11.2        | interleukin 18 receptor 1 precursor |
| IL18R1  | 2q11.2        | interleukin 1 receptor-like 1 precursor |
| IL1A    | 2q13          | interleukin 1, alpha proprotein |
| IL1B    | 2q13          | interleukin 1, beta proprotein |
| IL1R1   | 2q11.2        | interleukin 1 receptor, type 1 precursor |
| IL1R2   | 2q11.2        | interleukin 1 receptor, type 2 precursor |
| IL1R2   | 2q11.2        | interleukin 1 receptor-like 2 precursor |
| IL1RN, IL1RA | 2q13 | interleukin 1 receptor antagonist |
| IL6     | 7p15.3        | interleukin 6 |
| IL6R    | 1q21.3        | interleukin 6 receptor isofrom 2 precursor |
| IL8     | 4q13.3        | interleukin 8 precursor |
| IL8RA   | 2q35          | interleukin 8 receptor alpha |
| IL8RB   | 2q35          | interleukin 8 receptor beta |
| KL      | 13q13.1       | Klotho |
| LEP     | 7q32.1        | leptin precursor |
| LEPR    | 1p31.2        | leptin receptor |
| NFKB1   | 4q24          | nuclear factor kappa-B, subunit 1 |
| NFKB2   | 10q24.32      | nuclear factor of kappa light polypeptide gene |
| NOD2    | 16q12.1       | nucleotide-binding oligomerization domain |
| PAI1 (SERPINE1) | 7q22.1 | plasminogen activator inhibitor-1 |
| RETN    | 19p13.2       | Resistin |
| TNF     | 6p21.33       | tumor necrosis factor alpha |

doi:10.1371/journal.pone.0032958.t001
Table 2. Candidate gene characteristics.

| Gene Region       | Chr | Size (kb) | htSNPs* submitted | htSNPs* genotyped successfully |
|-------------------|-----|-----------|-------------------|-------------------------------|
| ADIPOQ            | 3q27.3 | 16 | 11 | 11 |
| ADIPOR1           | 1q23.1 | 18 | 14 | 13 |
| ADIPOR2           | 12p13.33 | 98 | 28 | 26 |
| CCL2              | 17q12 | 1.9 | 0 | 0 |
| CRP               | 1q23.2 | 2.3 | 0 | 0 |
| CTLA4             | 2q33.2 | 6.2 | 0 | 0 |
| IFH1              | 2q24.2 | 8.4 | 0 | 0 |
| IL10              | 1q32.1 | 5 | 18 | 16 |
| IL18              | 11q23.1 | 21 | 12 | 12 |
| IL1RL1/IL18R1     | 2q11.2 | 60 | 30 | 28 |
| IL1A/IL1B         | 2q13 | 64 | 24 | 19 |
| IL1R1             | 2q11.2 | 113 | 19 | 19 |
| IL1R2             | 2q11.2 | 37 | 24 | 20 |
| IL1RL2            | 2q11.2 | 52 | 12 | 12 |
| IL1RN/IL1RA       | 2q13 | 33 | 21 | 22 |
| IL6               | 7p15.3 | 4.8 | 19 | 18 |
| IL6R              | 1q21.3 | 63 | 23 | 20 |
| IL8               | 4q13.3 | 3.2 | 11 | 9 |
| IL8RA,B           | 2q35 | 43 | 16 | 16 |
| KL                | 13q13.1 | 50 | 0 | 0 |
| LEP               | 7q32.1 | 16 | 16 | 15 |
| LEPR              | 1p31.2 | 217 | 75 | 74 |
| NFKB1             | 4q24 | 116 | 43 | 41 |
| NFKB2             | 10q24.32 | 7.9 | 9 | 9 |
| NOD2              | 16q12.1 | 11 | 0 | 0 |
| PAI (SERpine)     | 7q22.1 | 12 | 2 | 0 |
| RETN              | 19p13.2 | 1.4 | 12 | 12 |
| TNF               | 6p21.33 | 2.8 | 15 | 15 |

*htSNPs = Haplotype tagged SNPs.
doi:10.1371/journal.pone.0032958.t002

Discussion

In a screen of 31 genes encoding members of the inflammatory pathway, we identified several with evidence for association with metabolic phenotypes in pregnant women. In particular the genes for cytokines including TNF, RETN, IL6, and IL8 were associated with glucose levels during pregnancy. Two receptors for cytokines (ADIPOR2 and LEPR) were associated with fasting and 1-hour C-peptide levels respectively.

A large number of GWAS have been carried out for type 2 diabetes and intermediate phenotypes such as fasting glucose levels [51,52,53,54,55,56,57,58,59,60,61,62,63,64,65]. However, no member of the inflammatory gene pathway was identified among the approximately 40 type 2 diabetes susceptibility loci identified to date nor was there evidence for association with diabetes related phenotypes. These observations can be due to several factors. For one GWAS genotyping arrays on average interrogate 80% of the human genome and therefore may not have exhaustive coverage of specific genetic regions of interest. Second, the effect size of the inflammatory genes may be too modest to reach genome-wide significance. Small effect sizes may still be detected in a candidate gene approach due to the reduced level of multiple testing correction that is required. In fact none of our findings reached genome wide significance and would therefore not have been detected in a GWAS. To evaluate the effect of genetic variations in genes in the inflammatory pathway on maternal glycemia during pregnancy with greater sensitivity than possible with current GWAS arrays, we designed a genotyping array with exhaustive coverage containing 458 SNPs in 31 genes belonging to the inflammatory pathway. In addition to tagging SNPs, we also included any known coding variants (cSNPs) mapping to the candidate genes and any SNPs previously identified as candidate SNPs (candSNPs) within the candidate genes (highlighted in Table 3).

While the loci with strongest evidence for association with metabolic traits in our study have not been reported in published GWAS, it is possible that they are associated at significance levels below the traditional cut-off reported in these studies. In fact multiple markers in both ADIPOR1 and IL8 do show evidence (p-value<0.01) for association with metabolic measures in the MAGIC consortium (Meta-Analyses of Glucose and Insulin-related traits Consortium) meta analysis results [61,66]. Notably there was no evidence for association with markers mapping to LEPR, TNF, IL6, ADOPOR2, or RETN even in the same SNP that was associated in our study as was the case for LEPR, TNF, IL6, and RETN. Markers within IL10 were nominally associated with glucose levels (p-value ~0.02) in the MAGIC consortium. One potential explanation for these observations is that some of our findings are unique to pregnancy (LEPR, TNF, IL6, and RETN) while others are also observed in the non-pregnant population. This would not be surprising since during pregnancy there is an increase of the inflammatory response due to both the general insulin resistant state of pregnancy and due to placentally derived factors.

Replication of genetic association results is critical for the validation of a potential susceptibility locus. In this study we analyze two large cohorts of European and Asian ancestry. Not only does this allow us to replicate our results from one cohort in the other, it also provides evidence for the generalizability of our findings to global populations. As is the case for most other common diseases, genetic analysis of the inflammatory gene pathway in metabolic phenotypes has been predominantly limited to populations of European ancestry. In our study 16 out of 17 of our strongest signals show evidence for association that is consistent in both populations (i.e. in the same direction).

The genetic effect of some of the inflammatory genes highlighted in this study has been previously studied. Variants within IL1B, IL1RN, IL6R, and PAI showed no evidence for association with type 2 diabetes in a large meta-analysis [67]. In an in-depth analysis Boraska et al tested for association between type 2 diabetes and nine tagging SNPs mapping to the TNF alpha/LTA gene region in 1520 cases and 2570 controls but found no evidence for association [68]. Hivert et al tested for association between 21 tagging SNPs in RETN and diabetes related traits in 2531 members of the Framingham Offspring Study cohort [69]. They found significant evidence for association 3’ to RETN with both resistin and fasting glucose levels. Although, they tested rs1423096 which is the variant we found to be associated with fasting glucose levels in this study (Table 4 and Figure 1A), the strongest evidence for association with glucose in the Framingham Offspring Study was with rs10401670 which maps 3,626 bp downstream of rs1423096. We detect no evidence of association between rs10401670 and any phenotypes tested in the HAPO cohort, Hivert et al carried out a similar analysis for 22 tagging SNPs mapping to the adiponectin gene (ADIPOQ). They found.
Table 3. Disease associated SNPs (candSNPs) and coding variant SNPs (cSNPs).

| Variant | Gene       | Chr. Location | Amino Acids |
|---------|------------|---------------|-------------|
| rs266729 | ADIPOQ     | 3q27.3        | 5’ of gene  |
| rs1501299 | ADIPOQ    | 3q27.3        | +276G>T     |
| rs17366743 | ADIPOQ | 3q27.3        | Tyr111His   |
| rs1024610 | CCL2      | 17q12         | 5’ of gene  |
| rs991804 | CCL2      | 17q12         | intronic    |
| rs1130864 | CRP       | 1q23.2        | intronic    |
| rs1800947 | CRP       | 1q32.2        | Leu184Leu   |
| rs3087243 | CTLA4     | 2q33.2        | 3’ of gene  |
| rs1990760 | IFIH1     | 2q24.2        | Ala946Thr   |
| rs16944  | IL1A/IL1B | 2q13          | intronic    |
| rs6731822 | IL1A/IL1B | 2q13          | Ile375Val   |
| rs1800871 | IL10      | 1q32.1        | 5’ of gene  |
| rs1800896 | IL10      | 1q32.1        | 5’ of gene  |
| rs1800872 | IL10      | 1q32.1        | 5’ of gene  |
| rs5744256 | IL18      | 11q23.1       | intronic    |
| rs4251961 | IL1RN, IL1RA | 2q13      | intronic    |
| rs315943 | IL1RN, IL1RA | 2q13      | 3’ of gene  |
| rs1800795 | IL6       | 7p15.3        | intronic    |
| rs952146 | IL6R      | 1q21.3        | 5’ of gene  |
| rs4537545 | IL6R      | 1q21.3        | intronic    |
| rs2229238 | IL6R      | 1q21.3        | 3’ UTR      |
| rs9536314 | KL        | 13q13.1       | Phe352Val   |
| rs12324931 | NOD2    | 16q12.1       | 5’ of gene  |
| rs6465787 | PAI1      | 7q22.1        | 5’ of gene  |
| rs2227631 | PAI1      | 7q22.1        | 5’ of gene  |

Evidence for association with the C allele of nonsynonymous SNP in exon 3 of the gene (rs17366743, Y111H) and diabetes and fasting plasma glucose levels. While we do not observe statistically significant evidence for association between this variant and glucose levels in our study, there is a trend for association with the C-allele of rs17366743 with 2-hour plasma glucose in European ancestry pregnant women (p-value = 0.081). It should be noted that, while T2D and elevated glucose levels during pregnancy are related phenotypes, they are not identical and may therefore have different susceptibility loci.

To date most of genetic studies of the role of inflammatory genes in metabolic phenotypes have been limited to one or two functional variants per gene and small sample sizes (n<1000). The impact of genetic variation within the leptin receptor (LEPR) on metabolic phenotypes has been intensively studied but the findings remain ambiguous. For instance, both alleles of the coding variant Gln223Arg (rs1137101) of the LEPR have shown evidence for association with increased BMI. While we did see nominal evidence for association between rs1137101 and HbA1C levels in the Thai population and 1-hour C-peptide levels in the Caucasian cohort (data not shown), these results did not reach significance as defined in our study. To date no major studies have been carried out to systematically assess the impact of this pathway on maternal metabolic phenotypes during pregnancy.

Past studies have shown clear evidence for association between protein levels of various members of the inflammatory pathway and metabolic phenotypes including insulin resistance, type 2 diabetes, and obesity. However these studies cannot provide evidence for the directionality of the effect – in other words does insulin resistance lead to perturbations of the inflammatory pathway or vice versa. Genetic studies such as the one presented here can address this question. Our data support the hypothesis that variation within the inflammatory pathway itself impacts metabolic phenotypes during pregnancy rather than the reverse. Although several of the findings presented here (association between TNF alpha and HbA1c, IL8 and 1-hour plasma glucose, IL6 and 1-hour plasma glucose, and RETN and fasting plasma glucose) show clear evidence for association in independent populations and therefore provide evidence of replication within this cohort, further studies are needed to determine whether the findings presented here are limited to pregnancy or can be expanded to other phenotypic groups.

Conclusions

Based on the genes surveyed in this study, we observed significant evidence for association between members of the inflammatory gene pathway and several metabolic measures during pregnancy. Specifically, cytokines were associated with fasting glucose (RETN), 1-hour plasma glucose levels during the OGTT (IL6, IL8) and HbA1C levels (IL10, TNF) while cytokine receptors were associated with fasting (ADIPOQ2) or 1-hour C-peptide (LEPR) levels. Thus, this study suggests that while some members of the inflammatory gene pathway are associated with metabolic phenotypes in pregnant women, the inflammatory pathway or vice versa. Genetic studies such as the one presented here can address this question. Our data support the hypothesis that variation within the inflammatory pathway itself impacts metabolic phenotypes during pregnancy rather than the reverse. Although several of the findings presented here (association between TNF alpha and HbA1c, IL8 and 1-hour plasma glucose, IL6 and 1-hour plasma glucose, and RETN and fasting plasma glucose) show clear evidence for association in independent populations and therefore provide evidence of replication within this cohort, further studies are needed to determine whether the findings presented here are limited to pregnancy or can be expanded to other phenotypic groups.
The pathway is unlikely to have a strong impact on maternal metabolism.

Methods

HAPO was an international, multi-center epidemiologic study conducted at 15 centers in 9 countries. The HAPO study was approved by the local institutional review board at each center. The centers contributing subjects studied in this work are Bangkok (Rajavithi Hospital, Ministry of Public Health), Manchester (Health and Social Care Trust Research Ethics Committee), Belfast (Health and Social Care Trust Research Ethics Committee), Brisbane (Mater Medical Research Institute), and Newcastle (Hunter Area Research Ethics Committee). All participants gave

Table 4. Results of Association Studies.

| Phenotype                     | Gene     | SNP     | Allele | Cohort  | MAF* | N** | Beta    | p     | Beta    | p     |
|------------------------------|----------|---------|--------|---------|------|------|---------|-------|---------|-------|
| 1 hour C-peptide (ug/L)      | ADIPOR1  | rs7554506 | A      | Eur. Anc. | 0.355 | 3830 | 0.021   | ***   | 0.013   | ***   |
|                              |          |         |        | Thai    | 0.086 | 1713 | −0.572  | 0.0026 | −0.065  | 0.0005 |
|                              |          |         |        | All     | 0.272 | 5543 | −0.052  | ***   | −0.068  | ***   |
| Fasting C-peptide (ug/L)     | ADIPOR2  | rs2041139 | A      | Eur. Anc. | 0.005 | 3800 | 0.548   | 0.00014 | 0.313   | 0.0085 |
|                              |          |         |        | Thai    | 0.043 | 1710 | 0.031   | ***   | 0.029   | ***   |
|                              |          |         |        | All     | 0.017 | 5510 | 0.138   | 0.02658 | 0.083   | ***   |
| 1 hour PG (mg/dl)            | IL6      | rs6954897 | G      | Eur. Anc. | 0.428 | 3833 | −2.245  | 0.00995 | −1.814  | 0.0060 |
|                              |          |         |        | Thai    | 0.056 | 1710 | −3.044  | ***   | −3.349  | ***   |
|                              |          |         |        | All     | 0.413 | 5543 | −2.291  | 0.00043 | −1.935  | 0.00231 |
| 1 hour PG (mg/dl)            | IL8      | rs2227306 | T      | Eur. Anc. | 0.439 | 3833 | −2.496  | 0.0020 | −2.331  | 0.00063 |
|                              |          |         |        | Thai    | 0.330 | 1709 | −0.399  |       | −0.434  | ***   |
|                              |          |         |        | All     | 0.405 | 5542 | −1.903  | 0.00086 | −1.748  | 0.00175 |
| 1 hour PG (mg/dl)            | IL8      | rs2886920 | T      | Eur. Anc. | 0.438 | 3833 | −2.552  | 0.00013 | −2.297  | 0.00040 |
|                              |          |         |        | Thai    | 0.426 | 1709 | −0.868  | ***   | −0.812  | ***   |
|                              |          |         |        | All     | 0.434 | 5542 | −2.045  | 0.00026 | −1.864  | 0.00065 |
| 1 hour C-peptide (ug/L)      | LEPR     | rs1171278 | T      | Eur. Anc. | 0.179 | 3833 | −0.040  | ***   | −0.056  | ***   |
|                              |          |         |        | Thai    | 0.097 | 1713 | −0.573  | 0.00086 | −0.620  | 0.00024 |
|                              |          |         |        | All     | 0.154 | 5546 | −0.110  | ***   | −0.167  | 0.03161 |
| 1 hour C-peptide (ug/L)      | LEPR     | rs1627238 | T      | Eur. Anc. | 0.179 | 3835 | −0.038  | ***   | −0.049  | ***   |
|                              |          |         |        | Thai    | 0.097 | 1713 | −0.564  | 0.00104 | −0.613  | 0.00029 |
|                              |          |         |        | All     | 0.154 | 5548 | −0.140  | ***   | −0.160  | 0.03911 |
| Fasting plasma Glucose (mg/dl)| RETN     | rs1423096 | A      | Eur. Anc. | 0.103 | 3833 | −0.843  | 0.00078 | −0.742  | 0.00136 |
|                              |          |         |        | Thai    | 0.207 | 1712 | −0.554  | 0.04514 | −0.470  | ***   |
|                              |          |         |        | All     | 0.135 | 5545 | −0.721  | 0.00011 | −0.620  | 0.00039 |
| HbA1c (%)                    | TNF      | rs1052248 | A      | Eur. Anc. | 0.264 | 3548 | 0.027   | 0.00427 | 0.029   | 0.00140 |
|                              |          |         |        | Thai    | 0.361 | 1567 | 0.063   | 0.00747 | 0.057   | 0.01296 |
|                              |          |         |        | All     | 0.294 | 5215 | 0.039   | 6.99×10^{-5} | 0.040   | 4.42×10^{-5} |
| HbA1c (%)                    | TNF      | rs11575839 | T      | Eur. Anc. | 0.017 | 3647 | 0.004   | ***   | 0.010   | ***   |
|                              |          |         |        | Thai    | 0.087 | 1568 | 0.121   | 0.00313 | 0.122   | 0.00257 |
|                              |          |         |        | All     | 0.039 | 5215 | 0.082   | 0.00052 | 0.086   | 0.00025 |

*MAF – minor allele frequency.
**Number of subjects included in the analysis.
***p-value < 0.05.

doi:10.1371/journal.pone.0032958.t004
Inflammatory Pathway Variation during Pregnancy

A. RETN FPG (Model 1)
B. IL8 thr PG (Model 1)
C. IL6 1 hr PG (Model 1)
D. ADIPO2 FCP (Model 1)
E. LEPR 1hr CP (Model 2)
F. TNFalpha HbA1c (Model 2)
written informed consent. An external Data Monitoring Committee provided oversight. Study methods have been published [70,71,72]. A brief overview is presented here.

Participants
All pregnant women at each field center were eligible to participate unless they had one or more exclusion criteria [70]. Gestational age and the expected date of delivery were determined as previously described [70].

Oral glucose tolerance test (OGTT)
All participants underwent a standard 75-gram OGTT between 24 and 32 weeks gestation and as close to 28 weeks as possible. Plasma glucose samples were collected at fasting and one- and two-hours after the glucose load. Samples for serum C-peptide were collected at fasting and one-hour time points (Table 5).

Anthropometric measurements
Height, weight, and blood pressure were measured at the OGTT visit using standardized procedures and calibrated equipment. Personal and demographic data were collected using standardized questionnaires. Race/ethnicity was self-identified (Table 5).

Unblinding
In order to make timely clinical decisions, aliquots of fasting and 2-hour OGTT or random plasma glucose (RPG) samples were analyzed enzymatically at field center laboratories [12]. Values were unblinded if FPG exceeded 5.8 mg/dl (105 mg/dL), if 2-hour PG exceeded 11.1 mg/dl (200 mg/dL), if RPG was ≥8.9 mg/dl (160 mg/dL) or if any PG value was less than 2.5 mg/dl (45 mg/dL). Otherwise, women, caregivers, and HAPO Study staff (except for laboratory personnel) remained blinded to glucose values. To avoid center-to-center analytical variation, aliquots of the OGTT glucose and C-peptide samples were analyzed at the HAPO Central Laboratory [73]. Those results were used for this report. A “Vitros 750” analyzer was used for glucose analysis and serum C-peptide was assayed on an Autodelfia instrument [73]. The technical errors for the glucose and C-peptide measurements were 2.0 and 4.2%, respectively.

DNA sample collection, preparation, and genotyping
A blood sample for DNA extraction was collected into an EDTA tube at 2-hours during the OGTT on women who specifically consented to this. Samples were frozen and shipped to Chicago. DNA was prepared using the automated Autopure LS from Qiagen. For this study we selected the two populations (Caucasians of European ancestry and Thai women from Bangkok) with the largest sample size and relatively homogenous ethnic ancestry.

SNP selection. Single nucleotide polymorphisms (SNPs) included in this study belong to three categories: (i) anonymous candidate gene SNPs or haplotype tagging SNPs (htSNPs) which map to genes belonging to the inflammatory pathway (Table 2), (ii) coding SNPs (cSNPs) that map to candidate genes (Table 3), and (iii) candidate SNPs (candSNPs) which have demonstrated evidence for association with inflammatory phenotypes in previous studies (Table 3). Anonymous candidate gene SNPs mapping to candidate genes or htSNPs were selected using the HAPMAP Tagger function [http://www.hapmap.org/cgi-perl/gbrowse/hapmap_B35/] to tag the entire genomic segment encompassing a given candidate gene in Caucasians (i.e. the CEPH trios genotyped by HAPMAP), Asian (Chinese and Japanese HAPMAP samples), and African (Yoruban HAPMAP trios) at an r2 of ≥0.8. A candidate gene region was identified as the coding region of the gene plus 20 kb upstream and 15 kb downstream of the gene. The SNPs consisted of 454 candidate gene tagging SNPs (htSNPs, Table 2), 54 candidate and/or coding
proportion of genotyping failures (r2<0.3). At the time of SNP selection neither results from GWA studies in T2D and related phenotypes nor panels of SNP based AIMS were available.

**Genotyping.** SNPs were genotyped using the Illumina Goldengate Assay on 32 sample universal BeadChip and iScan system (Illumina, San Diego CA) in a 1536 SNP bundle according to the manufacturers’ recommendations. Each 96 well plate consisted of 93 study samples and one CEPH (Centre d’Etude du Polymorphisme Humain) trio that served as a genotyping control. Two of the CEPH DNAs were randomly positioned on each tray while one DNA was plated in a fixed position on each tray allowing for unambiguous identification of each DNA tray and its orientation. Initial genotyping was carried out using the manufacturer supplied genotype clusters. Genotypes based on these cluster definition were used to identify poor quality DNAs. We defined poor quality DNAs as DNAs with p10GC<0.40, p50GC<0.60 or call rates less than 0.65. The poor quality DNAs were removed from the analysis as were two 96 well trays of DNAs with high rates of gender and replication errors. Samples were re-clustered and genotype clusters for each SNP were examined visually and cluster boundaries were adjusted as necessary. Finally, DNAs were re-genotyped using new cluster definitions. After re-clustering individuals were excluded due to: (i) phenotypic discrepancies including improper unblinding, nonsensical data, incorrect ethnicity, or “bad” IDs, (ii) missing genotypes for >6% of SNPs, or (iii) mom-baby pairs with Mendelian errors for >5% of SNPs.

Of the 508 inflammatory gene SNPs that were submitted for genotyping, 32 markers were dropped due to poor resolution of genotyping clusters. A further 6 SNPs were dropped due to high proportion of genotyping failures (>1% of DNA samples), and 12 SNPs were dropped due to low minor allele frequency (MAF<0.01). Thus 458 SNPs fulfilled our quality control criteria. The average call rate of the SNPs used in the association analyses was 99.9% and average minor allele frequency (MAF) was 0.28. The replication error rate in the Centre D’Etude du Polymorphisme Humain (CEPH) trio was <0.01%. Of the 6218 unique DNA samples submitted for genotyping 5549 subjects (1713 Thai and 3836 Northern European ancestry) remained after data cleaning, 60 DNA samples failed Illumina genotyping quality scores, 441 samples had missing genotypes at greater than 6% of SNPs and 168 samples were dropped due to excessive Mendelian errors (>5%), or due to phenotypic discrepancies including improper unblinding, nonsensical data, incorrect ethnicity, or incorrect sample identifiers. Average call rate for the 5549 samples used in the genetic analyses was >99%.

**Genetic Analysis**

Principal Component Analysis (PCA): We used SMARTPCA in the EIGENSOFT software package to calculate principal components for each subject using 145 AIMS. The AIMS consisted of 50 previously identified AIMS and 95 independent hSNPs from this study. These independent hSNPs were chosen by selecting one SNP from each of the genomic regions interrogated in the complete candidate gene 1536 SNP panel. These genomic regions possessed the greatest sum of inter population allele frequency differences in the three HapMap Phase I populations, and were not in linkage disequilibrium (r2<0.3) with any SNP showing evidence for association (p<0.01) with the six primary phenotypes investigated (see below). This set of 145 SNPs was sufficient to differentiate between the Thai and Caucasians, although choosing a second SNP per genomic region that met the first two conditions above and was not in linkage disequilibrium (r2<0.3) with the first SNP selected from the region improved performance. The principal components derived from these analyses were used as covariates to adjust for ethnic variation in the association tests.

**Association Testing.** We tested for association between SNPs and six maternal phenotypes in the complete cohort while adjusting for field center and ethnicity and in Thai and Caucasian cohorts separately. Phenotypes tested were glucose levels (fasting, 1-hour and 2-hour), C-peptide levels (fasting and 1-hour), and HbA1c levels. All phenotypic measurements were obtained at the OGTT. Associations were assessed through linear regressions, with single outcomes under an additive model using PLINK, version 1.05 [74], integrated into the BC/SNPmax database, version 2.5.9 (Biocomputing Platforms Ltd., Espoo, Finland). Natural log (ln) transformation was used to achieve normal distribution for C-peptide levels. Mendelian error checking of genotypes was performed with PedCheck, version 1.00 [75] through BC/SNPmax.

Two models were analyzed for each outcome. Model I was a minimally adjusted model that included adjustment for field center, ethnicity using the first two principal components and four variables that are major covariates: maternal age, parity, gestational age at OGTT, and neonatal gender. Model II was the fully adjusted model, adjusting for all covariates included in model I as well as MAP at OGTT, maternal BMI at OGTT, and maternal height at OGTT.

**Acknowledgments**

Members of the HAPO Study Cooperative Research Group are listed in the Appendix of: HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcomes. N Engl J Med. 2008;358:1991–2002.

**Author Contributions**

Conceived and designed the experiments: MU MGH WLL LPL ARD NJC. Performed the experiments: LPL CA NJ. Analyzed the data: MU MGH HL RMF. Wrote the paper: MU MGH LPL RMF ARD NJC.

**References**

1. Olefsky JM, Glass CK. (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219–246.
2. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, et al. (2000) Elevated obesity in men. J Hum Genet 48(12): 651–655.
3. Berthier MT, Paradis AM, Tchernof A, Bergeron J, Prud’homme D, et al. (2005) Elevated interleukin 6-174G/C polymorphism is associated with indices of obesity and hyperandrogenism. Obes Res 13: 987–996.
4. Berthier MT, Paradis AM, Tchernof A, Bergeron J, Prud’homme D, et al. (2006) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219–246.
5. Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, et al. (2002) Weight loss reduces interleukin-111 levels in obese women. J Clin Endocrinol Metab 85: 3384–3392.
6. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, et al. (2003) Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab 88: 1053–1058.
7. Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, et al. (2003) Meal modulation of circulating interleukin 10 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutrition 78: 1135–1140.
Inflammatory Pathway Variation during Pregnancy

8. Fasshauer M, Kralisch S, Klier M, Losner U, Bluhmer M, et al. (2004) Interleukin-6 is a positive regulator of tumor necrosis factor alpha-induced adipose-related protein in 3T3-L1 adipocytes. FEBS Letters 560(1–3): 153–157.

9. Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, et al. (2000) Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49: 517–520.

10. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, et al. (2001) Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86(3): 1154–1159.

11. Hamid YH, Rose CS, Urhammer SA, Glemser C, Nolte R, et al. (2005) Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 48: 251–260.

12. Ilg T, Bongardt F, Schloeper A, Muller-Scholze S, Rathmann W, et al. (2004) Significant association of the interleukin-6 gene polymorphisms C-174G and A-59G with type 2 diabetes. J Clin Endocrinol Metab 89: 5053–5058.

13. Lagatso D, Bastard JP, Auxlar M, Mauchi M, Capoex J, et al. (2003) Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 312(1): 372–379.

14. Meuller S, Martin S, Roening W, Hanifi-Moghadam P, Rathmann W, et al. (2002) Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated-acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 45(6): 605–612.

15. Moszynski V, Sato T, Shibutani Y, Aoki E, Tsutsumi Z, et al. (2003) Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolol Clin Exp 52: 605–608.

16. Pickel JC, Mattiock MB, Chassad GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40(11): 1286–1292.

17. Ronner V, Nagaei I, Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is like IL-1 beta and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278(46): 45777–45784.

18. Wallenius V, Ahraaten B, Rudling M, Carlsten H, et al. (2002) Mechanism by which high-dose aspirin improves glycemic control in type 2 diabetes. J Clin Invest 109: 1321–1326.

19. Yuan M, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of IkappaB kinase-beta. Nature 396: 77–80.

20. Frischboehm A, Schoenen BE, Bernier R, Goldfine AB (2000) Salabate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 23: 289–294.

21. Hunders RS, Petersen KF, Maeyerson AB, Randhawa PS, Inzucchi S, et al. (2002) Mechanism by which high-dose aspirin improves glycemic control in type 2 diabetes. J Clin Invest 109: 1321–1326.

22. Buechel LS, Vasan RS, Barlow BJ, Cade A, D'Agostino RB, et al. (2005) C-reactive protein and tumor necrosis factor-alpha in gestational hyperglycemia. J Endocrinol Invest 28: 779–786.

23. Kinalski M, Teleiko B, Kuzmicki M, Kretowski A, Kinalski I (2005) Tumor necrosis factor alpha system and plasma adipocin concentration in women with gestational diabetes. Horm Metab Res 37: 450–454.

24. Williams MA, Qiu C, May-Rivera M, Vadchachoria S, Song T, et al. (2004) Plasma adipocin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. J Clin Endocrinol Metab 89: 2306–2311.

25. Low L, Metzger BE, Lowe WL Jr, Dyer AR, McDade TW, et al. (2010) Inflammatory mediators and glucose in pregnancy: results from a subset of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. J Clin Endocrinol Metab 95: 5427–5434.

26. Ziegler E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, et al. (2008) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316: 1336–1341.

27. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 1316: 1341–1345.

28. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, et al. (2007) A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nature 379: 770–775.

29. Ziegler E, Scott LJ, Saxena R, Voight BF, Marchini JL, et al. (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40: 638–645.

30. Yaukka K, Miyake H, Horikawa Y, Hara K, Owaia H, et al. (2008) Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 40: 1092–1097.

31. Unoki H, Takahashi A, Kagawauchi T, Hara K, Horikoshi M, et al. (2005) SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 37: 1089–1102.

32. Prokopienko I, Langenberg C, Florea JC, Saxena R, Soranzo N, et al. (2009) Variants in MTNR1B influence fasting glucose levels. Nat Genet 41: 77–81.

33. Bouaiza-Naji N, Bonnefond A, Cavalcanti-Poncet C, Sparso T, Holmkvist J, et al. (2009) A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41: 89–94.

34. Dupuis J, Langenberg C, Prokopienko I, Saxena R, Soranzo N, et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42: 105–116.
62. Voight BF, Scott LJ, Steinthorsson E, Morris AP, Dina C, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42: 579–589.

63. Tsai FJ, Yang CF, Chen CC, Chuang LM, Lu CH, et al. A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet 6: e1000417.

64. Li Q, Cornelis MC, Kraft P, Stampf K, Linda Kao WH, et al. Genetic variants at 2q37 are associated with susceptibility to type 2 diabetes. Hum Mol Genet 19: 2706–2715.

65. Saxena R, Voight BF, Lysenko V, Burt NP, de Bakker PI, et al. (2007) Genome-wide association study identifies loci for type 2 diabetes and triglyceride levels. Science 316: 1331–1336.

66. Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, et al. (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nature Genetics 42: 142–148.

67. Rafiq S, Melzer D, Weedon MN, Lango H, Saxena R, et al. (2008) Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. Diabetologia 51: 2205–2213.

68. Boraiza V, Rayner NW, Groves CJ, Feelying TM, Diakite M, et al. (2010) Large-scale association analysis of TNF/IFNA gene region polymorphisms in type 2 diabetes. BMC medical genetics [electronic resource] 11: 69.

69. Hivert MF, Manning AK, McAteer JB, Dupuis J, Fox CS, et al. (2009) Association of variants in REI1 with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study. Diabetes 58: 750–756.

70. Huth C, Illig T, Herder C, Gieger C, Grallert H, et al. (2009) Joint analysis of IL10 polymorphisms and laboratory parameters to identify vascular related complications. Current Pharmaceutical Design 15: 1914–1920.

71. Li Q, van Dijk MM, Lange CN, Nord AS, et al. (2008) Polymorphisms of the IL1-1 receptor antagonist gene (IL1RN) is associated with altered circulating IL-1RA levels. Genes & Immunity 9: 344–351.

72. Reiner AP, Auffenberg MM, Lange CN, Carlson CS, Nord AS, et al. (2008) Polymorphisms of the IL1-1 receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation. Arteriosclerosis, Thrombosis & Vascular Biology 28: 1407–1412.

73. Huth C, Illig T, Herder C, Gieger C, Grallert H, et al. (2007) The IL1RN promoter rs4251961 correlates with IL-1 receptor antagonist concentrations in human infection and is differentially regulated by GATA-1. Journal of Immunology 179: 2329–2335.

74. Huth C, Illig T, Herder C, Gieger C, Grallert H, et al. (2006) IL6 gene polymorphisms and type 2 diabetes: joint analysis of individual participants’ data from 21 studies. Diabetes 55: 2915–2921.

75. Li Q, van Dijk MM, Meigs JB, Manson JE, Hunter D, et al. (2006) Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Human Molecular Genetics 15: 1914–1920.
110. Freathy RM, Weedon MN, Melzer D, Shields B, Hitman GA, et al. (2006) The functional “KL-VS” variant of KLOTHO is not associated with type 2 diabetes in 5028 UK Caucasians. BMC Med Genet 7: 51.

111. Kathiresan S, Gabriel SB, Yang Q, Lechner AL, Larson MG, et al. (2005) Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 112: 1728–1735.